LifeMD, Inc. functions as a direct-to-patient telehealth enterprise, linking individuals with healthcare professionals throughout the United States for a diverse array of medical concerns. These services encompass everything from personalized concierge care to specialized fields such as men's sexual health and dermatology. The company operates a portfolio of distinct telehealth brands. ShapiroMD is dedicated to comprehensive hair loss solutions, offering virtual consultations, prescription medications, unique over-the-counter products, an FDA-approved medical device, and specialized compounded topical treatments for both male and female hair loss. RexMD provides virtual medical treatment from licensed providers for various men's health requirements. LifeMD Primary Care is a subscription-based, mobile-first platform delivering personalized virtual primary, urgent, and chronic care, integrating online consultations, prescription services, diagnostics, and imaging. Cleared focuses on customized treatments for allergy, asthma, and immunological conditions. Nava MD serves as a female-oriented tele-dermatology and skincare brand, facilitating virtual medical consultations with dermatologists and other experts. Beyond its healthcare focus, LifeMD also manages PDFSimpli, an online software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents. The company distributes its products and services directly to consumers, through e-commerce channels, and via third-party partner networks. Initially established in 1994 as Conversion Labs, Inc., the company officially rebranded to LifeMD, Inc. in February 2021. Its corporate headquarters are located in New York, New York.
UPDATE - LifeMD Reports Second Quarter 2026 Results
LifeMD reported Q2 revenue of $47.3 million, within guidance, while adjusted EBITDA loss improved 21% sequentially to $3.5 million on gross margin expansion to 89%.
Management revised full-year 2026 revenue guidance down to $205.5 million to $212.5 million and adjusted EBITDA to a range of a $6 million loss to breakeven, lowering prior expectations due to the strategic shift to branded therapies.
Despite the reduced annual outlook, the company projects a Q4 exit revenue run rate of $250 million and $22 million of annualized adjusted EBITDA, highlighting growth in weight management subscribers and new partnerships.